Rafael Ríos
A5101595710- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Chemokine receptors and signaling
- Acute Myeloid Leukemia Research
- vaccines and immunoinformatics approaches
- HIV/AIDS drug development and treatment
- Drug Transport and Resistance Mechanisms
- Monoclonal and Polyclonal Antibodies Research
- Cancer Genomics and Diagnostics
- Histone Deacetylase Inhibitors Research
- PI3K/AKT/mTOR signaling in cancer
- Parathyroid Disorders and Treatments
- Antifungal resistance and susceptibility
- Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Glycosylation and Glycoproteins Research
- Birth, Development, and Health
- Fungal Infections and Studies
Hospital Universitario Puerta de Hierro Majadahonda
2022-2024
Hospital Universitario Virgen de las Nieves
2015-2024
Centro de Investigación en Red en Enfermedades Cardiovasculares
2024
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública
2019-2023
Instituto de Investigación Biosanitaria de Granada
2013-2022
Centro de Investigación Biomédica en Red
2022
Institut Català d'Oncologia
2022
University of Girona
2022
Institut d'Investigació Biomèdica de Girona
2022
Complejo Hospitalario Universitario de Granada
2015-2020
Assessing measurable residual disease (MRD) has become standard with many tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain, particularly when assessed by next-generation flow (NGF) cytometry. Thus, we aimed to determine applicability and sensitivity MRD-negative criterion defined International Myeloma Working Group (IMWG).In PETHEMA/GEM2012MENOS65 trial, 458 patients newly diagnosed MM had longitudinal assessment after six induction cycles bortezomib,...
PURPOSE Patients with multiple myeloma (MM) may show patchy bone marrow (BM) infiltration and extramedullary disease. Notwithstanding, quantification of plasma cells (PCs) continues to be performed in BM since the clinical translation circulating tumor (CTCs) remains undefined. PATIENTS AND METHODS CTCs were measured peripheral blood (PB) 374 patients newly diagnosed MM enrolled GEM2012MENOS65 GEM2014MAIN trials. Treatment included bortezomib, lenalidomide, dexamethasone induction followed...
The recognition of pathogen-derived structures by C-type lectins and the chemotactic activity mediated CCL2/CCR2 axis are critical steps in determining host immune response to fungi. present study was designed investigate whether presence single nucleotide polymorphisms (SNPs) within DC-SIGN, Dectin-1, Dectin-2, CCL2 CCR2 genes influence risk developing Invasive Pulmonary Aspergillosis (IPA). Twenty-seven SNPs were selected using a hybrid functional/tagging approach genotyped 182...
Here, we investigated for the first time frequency and number of circulating tumor plasma cells (CTPC) in peripheral blood (PB) newly diagnosed patients with localized systemic cell neoplasms (PCN) using next-generation flow cytometry (NGF) correlated our findings distinct diagnostic prognostic categories disease. Overall, 508 samples from 264 PCN patients, were studied. CTPC detected PB all active multiple myeloma (MM; 100%), smoldering MM (SMM) (100%), more than half (59%) monoclonal...
Abstract Monitoring of the monoclonal protein (M-protein) by electrophoresis and/or immunofixation (IFE) has long been used to assess treatment response in multiple myeloma (MM). However, with use highly effective therapies, M-protein becomes frequently undetectable, and more sensitive methods had be explored. We applied IFE mass spectrometry (EXENT&FLC-MS) serum samples from newly diagnosed MM patients enrolled PETHEMA/GEM2012MENOS65 obtained at baseline (n = 223), after induction 183),...
Abstract Purpose: Undetectable measurable residual disease (MRD) is a surrogate of prolonged survival in multiple myeloma. Thus, treatment individualization based on the probability patient achieving undetectable MRD with singular regimen could represent new concept toward personalized treatment, fast assessment its success. This has never been investigated; therefore, we sought to define machine learning model predict at onset Experimental Design: study included 487 newly diagnosed patients...
The existence of patients with multiple myeloma (MM) and light-chain (AL) amyloidosis who present a monoclonal gammopathy undetermined significance (MGUS)-like phenotype has been hypothesized, but methods to identify this subgroup are not standardized its clinical is properly validated.An algorithm having MGUS-like was developed on the basis percentages total bone marrow (BM) plasma cells (PC) clonal PC within BM compartment, determined at diagnosis using flow cytometry in 548 MGUS 2,011...
Early treatment of high-risk smoldering myeloma has been shown to delay progression multiple (MM). We conducted this trial with curative intention using a approach employed for newly diagnosed patients MM.
Abstract The value of minimal residual disease (MRD) status by bone marrow and imaging analysis as independent prognostic factors has been well established in multiple myeloma (MM). Nevertheless data about their potential complementarity for a more accurate assessment are limited. With this aim, we retrospectively analyzed the prediction outcome with combination PET‐CT MRD, assessed multiparameter flow cytometry (MFC) 103 patients newly diagnosed MM. We confirmed benefit terms...
Belantamab-mafodotin (belamaf) is a novel antibody-drug conjugate targeting B-cell maturation antigen that showed anti-myeloma activity in patients with relapsed and refractory multiple myeloma (RRMM). We performed an observational, retrospective, multicenter study aimed to assess the efficacy safety of single-agent belamaf 156 Spanish RRMM. The median number prior therapy lines was 5 (range, 1-10), 88% were triple-class refractory. Median follow-up 10.9 months 1-28.6). overall response rate...
Abstract Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of cell diversity may be key to understanding the success immunomodulatory drugs and failure PD-1 blockade in tumors such as multiple myeloma (MM). Here, we use single-cell RNA receptor sequencing characterize bone marrow from healthy adults ( n = 4) patients with precursor 8) full-blown MM 10). Large clones expressed immune checkpoints, suggesting a potentially dysfunctional...